XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements
Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patientsWholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trialThe company is planning the construction of a new lab and manufacturing space up to 32,000 square feet in Biberach, GermanyPilot project involving rapid COVID-19 PCR tests…